Academic detailing outreach to primary care providers significantly increases prescribing rates of FDA-approved medications for alcohol use disorder (naltrexone, topiramate, disulfiram) among veterans.
Positive Phase 2 topline data for elunetirom, a CNS-targeted thyroid receptor agonist, demonstrates rapid and significant efficacy as an adjunctive treatment for bipolar depression with a favorable safety profile.
Autobahn Therapeutics reported positive Phase 2 topline data for elunetirom in bipolar depression, showing rapid, robust, and durable antidepressant effects.
Research suggests a saliva-based biomarker may predict individual response to ADHD medications, offering a potential tool for precision prescribing.
This case report highlights the risk of catatonia precipitated by D2 receptor antagonist antiemetics (metoclopramide and domperidone) in patients with multiple sclerosis, emphasizing the need for caution when prescribing these agents to individuals with blood-brain barrier compromise.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Feb 16 – Jun 06)
- Consider early tapering from opioid agonist treatment only after 12-48 months to avoid significantly increased all-cause mortality risk associated with premature discontinuation.
- Exercise extreme caution when prescribing D2 receptor antagonist antiemetics like metoclopramide to patients with conditions compromising the blood-brain barrier due to the precipitated risk of catatonia.
- Utilize academic detailing outreach strategies in primary care settings to significantly increase prescribing rates of FDA-approved alcohol use disorder medications such as naltrexone and topiramate.
- Reassess the long-term efficacy of antidepressants for relapse prevention beyond 12 months, as recent evidence suggests these benefits may be overstated.
- In patients with comorbid bipolar disorder and alcohol use disorder, prioritize N-acetylcysteine over gabapentin to target dorsal anterior cingulate cortex glutamate levels and reduce heavy drinking days.
- Monitor for antipsychotic-induced weight gain using pharmacogenomic testing profiles, as genetic factors play a significant role in predicting this adverse effect in severe mental illness.
- Use intranasal midazolam (BXCL501) for rapid reduction of agitation in bipolar disorder and schizophrenia patients within home settings when immediate symptom control is required.
- Consider clozapine as a viable off-label option for severe irritability in autism spectrum disorder, supported by real-world evidence comparing its profile favorably to standard adolescent schizophrenia treatments.
- Be aware that regulatory hurdles may delay the availability of novel ADHD pharmacotherapies like CTx-1301, requiring reliance on current approved options while monitoring emerging trial data.
Drug Development 3
A clinical trial is evaluating the dopamine D2 and D3 receptor occupancy of SIPI6398, a novel investigational agent for schizophrenia.
A Phase 2a open-label trial evaluates the safety and antidepressant efficacy of inhaled mebufotenin (GH001), a rapid-acting 5-HT agonist, in adult patients with postpartum depression.
Pharmacogenomics 2
New pharmacogenomic testing is available to help explain individual variability in response to ADHD medications, offering a clinical tool for optimizing prescribing decisions.
This meta-analysis synthesizes current evidence on genetic factors associated with antipsychotic-induced weight gain in adults with severe mental illness, highlighting the role of pharmacogenomics in predicting this adverse effect.
Clinical Pearl 1
A randomized crossover trial found that N-acetylcysteine, but not gabapentin, significantly reduced dorsal anterior cingulate cortex glutamate levels and heavy drinking days in patients with comorbid bipolar disorder and alcohol use disorder, supporting further mechanistic trials of glutamatergic modulation.
Journal Article 2
A new study challenges the long-term efficacy of antidepressants for relapse prevention beyond 12 months, suggesting benefits may be overstated.
This retrospective study compares the clinical profiles and treatment outcomes of clozapine in adolescents with schizophrenia versus those with autism spectrum disorder, providing real-world evidence for its off-label use in severe ASD irritability.
Diagnosis & Treatment 3
A study links psilocybin to a reduction in depression symptoms, highlighting its potential as a novel therapeutic agent for mood disorders.
New analysis confirms BXCL501 (intranasal midazolam) effectively reduces agitation in patients with bipolar disorder and schizophrenia when administered at home.
A single dose of psilocybin produces rapid and long-lasting improvements in depression, highlighting its potential as a novel pharmacotherapy for mood disorders.
Policy & Regulation 3
The FDA issued a Complete Response Letter for CTx-1301, a potential new treatment for ADHD, indicating regulatory hurdles for this psychopharmacologic candidate.
Australia has authorized the prescription of psilocybin for treatment-resistant depression, marking a significant regulatory shift for this psychedelic psychiatric treatment.
The FDA is reviewing a new drug application for narcolepsy and has approved a clinical trial for psilocybin in PTSD, highlighting ongoing regulatory and research developments in psychiatric pharmacology.
Substance Use 1
Early tapering from opioid agonist treatment (methadone or buprenorphine/naloxone) increases taper completion rates but significantly raises all-cause mortality risk compared to waiting 12-48 months.